Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
PR Newswire•14/10/2026•16:30 ET
0
Key Highlights
- ➤Kristine Ball appointed to Enliven’s board, effective immediately
- ➤Enliven plans pivotal Phase 3 relcobatinib trial before year-end 2026
- ➤FDA aligned with final ENABLE-2 Phase 3 trial design
- ➤Relcobatinib targets previously treated chronic myeloid leukemia patients
Expert Statements
Rick Fair, Chief Executive Officer of Enliven Therapeutics
“We are pleased to welcome Kristine Ball to our Board. Her experience helping companies transition from clinical development to commercial operations will bring valuable perspective as we prepare to initiate our pivotal Phase 3 trial of relcobatinib before year-end and plan for commercialization. We look forward to her contributions as we work to deliver a differentiated treatment option for people living with chronic myeloid leukemia and create long-term value for our shareholders.”
Kristine Ball, Board member of Enliven Therapeutics
“Having seen the impact of CML on a member of my family, I feel a personal connection to Enliven's mission of helping people with CML not only live longer, but live better.”
Kristine Ball, Board member of Enliven Therapeutics
“I'm excited to contribute as the Company navigates this transition and prepares for potential commercialization. I look forward to working with the Board and leadership team to help advance relcobatinib through pivotal development and prepare Enliven for its next stage of growth.”
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year PR Newswire
Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Get started
Create a free account to read the full story.